News | November 05, 2010

Final Patient Enrolled for PAD Study

November 5, 2010 – The final patient has been enrolled in a trial studying a balloon-expandable covered stent for those with occlusive disease of the iliac artery. The iCARUS trial is investigating the iCast stent, made by Atrium Medical.

Iliac artery occlusive disease is one form of peripheral arterial disease (PAD). Patients with PAD typically have intermittent upper and lower leg pain, commonly known as “claudication” or “rest pain.” Lower extremity leg pain is often caused by decreased blood flow due to a narrowing or thrombotic occlusion of peripheral blood vessels. It can also be a result of atherosclerosis along the luminal walls of leg arteries, including the common iliac, external iliac, femoral and popliteal vessels.

In the study, the stent is used to re-open diseased iliac arteries, which feed blood flow to the legs from the aorta.

“I am thrilled that we have completed enrollment in the iCARUS trial,” said John R. Laird, M.D., U.C. Davis vascular center in Sacramento, Calif., and principal investigator of the study. “This is an important study that will help define the role of the iCast covered stent for the treatment of iliac occlusive disease.”

The iCast balloon-expandable covered stent is a micro-thin biomaterial film encapsulating a stainless steel slotted tube stent. Since it is pre-mounted by the company onto a balloon delivery catheter, it offers single-operator deployment through a very small diameter introducer sheath, without the need for surgery. The delivery system is compatible with 0.035-inch guidewires.

The stent is currently an investigational device in the United States and is currently FDA-approved for treating tracheobronchial strictures.

For more information: www.atriummed.com.


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now